Corbus Pharmaceuticals
CRBP
14 hedge funds and large institutions have $9.5M invested in Corbus Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 14 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
9.68% more ownership
Funds ownership: 0% → 9.68% (+9.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$5.87M |
| 2 |
Perceptive Advisors
New York
|
+$2.92M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.12M |
| 4 |
BlackRock Fund Advisors
San Francisco,
California
|
+$175K |
| 5 |
DAFNA Capital Management
Los Angeles,
California
|
+$123K |
Top Sellers
CRBP Hedge Fund Activity: Q2 2015 in Review
14 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2015, worth a combined $9.5M.
Buyers outnumbered sellers: 14 funds opened new CRBP positions and 0 closed out — a net gain of 14 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Knoll Capital Management, opening a new position worth an estimated $5.87M.
- 14 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $9.5M of Corbus Pharmaceuticals stock for Q2 2015.
- 14 funds opened new Corbus Pharmaceuticals positions in Q2 2015 and 0 closed out, a net change of +14 holders.
- The largest Corbus Pharmaceuticals buyer in Q2 2015 was Knoll Capital Management, an estimated $5.87M added.
Based on aggregated 13F filings for Q2 2015.